Tokyo Tape
Sign in
← Olympus

Quarterly report · Q3

7733.TEDINET S100Q5QA
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥641.5bn2022-04-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥224.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS (5-year summary)
Revenue¥750.1bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥547.2bn2021-04-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥187.1bn2021-10-01 → 2021-12-31dCons.Revenue IFRS (5-year summary)
Operating income¥142.6bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥49.0bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥102.2bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥31.6bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥139.4bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥50.0bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥141.7bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥97.0bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥28.6bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥108.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥41.4bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥115.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥87.7bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥25.3bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥108.4bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥41.4bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥87.8bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥25.3bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥1.39Tat 2022-12-31Cons.Assets IFRS
Total assets¥1.36Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.29Tat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥787.0bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥846.6bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥605.6bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥511.4bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥480.3bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥395.5bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥604.5bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥510.2bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥479.1bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥175.7bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥211.3bnat 2022-12-31Cons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥302.6bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥275.1bnat 2021-12-31Cons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥54.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥169.7bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥115.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥37.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥71.0bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥57.1bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥112.4bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥40.7bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥9.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥85.122022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥32.642022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥90.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥68.192021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.662021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥85.042022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥32.62022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥90.172021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥68.162021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.652021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio43.4%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio37.6%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio37.1%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥15.3bn
jpcrp040300-q3r_E02272-000Endoscopic Solutionsreportable segmentsegment profit2022-04-01 → 2022-12-31¥110.7bn
jpcrp040300-q3r_E02272-000Otherreportable segmentsegment profit2022-04-01 → 2022-12-31−¥917m
jpcrp040300-q3r_E02272-000Therapeutic Solutionsreportable segmentsegment profit2022-04-01 → 2022-12-31¥48.1bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥157.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥31.7bn
jpcrp040300-q3r_E02272-000Endoscopic Solutionsreportable segmentsegment profit2021-04-01 → 2021-12-31¥91.6bn
jpcrp040300-q3r_E02272-000Otherreportable segmentsegment profit2021-04-01 → 2021-12-31−¥1.5bn
jpcrp040300-q3r_E02272-000Therapeutic Solutionsreportable segmentsegment profit2021-04-01 → 2021-12-31¥43.8bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥134.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 734
ItemContextValueUnit
Sales to external customers IFRSPrior1YTDDuration547184000000JPY
Intersegment sales IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember－JPY
Intersegment sales IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember－JPY
Intersegment sales IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember291000000JPY
Intersegment sales IFRSPrior1YTDDuration_ReportableSegmentsMember291000000JPY
Intersegment sales IFRSPrior1YTDDuration_ReconcilingItemsMember-291000000JPY
Intersegment sales IFRSPrior1YTDDuration－JPY
Net sales IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember333701000000JPY
Net sales IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember203714000000JPY
Net sales IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember10060000000JPY
Net sales IFRSPrior1YTDDuration_ReportableSegmentsMember547475000000JPY
Net sales IFRSPrior1YTDDuration_ReconcilingItemsMember-291000000JPY
Net sales IFRSPrior1YTDDuration547184000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember91600000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember43845000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember-1480000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember133965000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-31734000000JPY
Operating profit loss IFRSPrior1YTDDuration102231000000JPY
Finance income IFRSPrior1YTDDuration970000000JPY
Finance costs IFRSPrior1YTDDuration6191000000JPY
Profit loss before tax IFRSPrior1YTDDuration97010000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember624000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember-47000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember－JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_ReportableSegmentsMember577000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration577000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember24840000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember12438000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember857000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReportableSegmentsMember38135000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReconcilingItemsMember4793000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration42928000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember1898000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember417000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember－JPY
Impairment losses pl IFRSPrior1YTDDuration_ReportableSegmentsMember2315000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReconcilingItemsMember862000000JPY
Impairment losses pl IFRSPrior1YTDDuration3177000000JPY
Sales to external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember398990000000JPY
Sales to external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember233942000000JPY
Sales to external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember8613000000JPY
Sales to external customers IFRSCurrentYTDDuration_ReportableSegmentsMember641545000000JPY
Sales to external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Sales to external customers IFRSCurrentYTDDuration641545000000JPY
Intersegment sales IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember－JPY
Intersegment sales IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember－JPY
Intersegment sales IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember211000000JPY
Intersegment sales IFRSCurrentYTDDuration_ReportableSegmentsMember211000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass